Germany Remote Patient Monitoring Device Market Research Report - Industry Analysis and Forecast to 2025

21 September 2018, The Germany Remote Patient Monitoring Devices Market size is expected to reach USD 120.4 million by 2025. This growth is attributed to rising population and trend of independent living, along with demand for cost-effective treatment and quality care. Remote patient monitoring devices are used for managing and monitoring a wide array of health conditions. These devices find application in chronic disease management, care integrator, progress tracker, an early warning system, capacity builder, and confidence builder.

Stringent government policies and favorable regulations by WHO in Germany regarding usage of remote patient monitoring devices are encouraging companies to develop drugs for treatment of chronic diseases. These diseases include cardiovascular diseases (CVDs), cancer, diabetes mellitus (DM), and chronic respiratory diseases. Penetration of remote patient monitoring devices in the German market supports local clinical research organizations (CROs) in their clinical research trials and ensures ease of monitoring, which facilitates drug discovery process.

Browse Details of Report @ https://www.hexaresearch.com/research-report/germany-remote-patient-monitoring-device-market

Thus, growing cases of chronic disorders are expected to serve as a high impact rendering factor for the Germany remote patient monitoring device industry. Cancer, CVDs, sleep disorder, and weight management and fitness monitoring are the key application segments analyzed in the Germany remote patient monitoring devices industry. Cardiovascular diseases segment is one of the largest application segments. This is mainly due to increasing number of patients suffering from diseases such as cardiac hypertension as they need regular blood pressure monitoring due to frequent fluctuations.

The use of remote patient monitoring devices in post-acute care aids in self-health management. Increasing demand for self-management skills and tools is projected to propel the market growth in the next few years. Escalating demand for independent care, especially in post-operative care is further anticipated to be a major factor driving the industry growth. Growing geriatric population, as they are highly susceptible to chronic conditions, such as diabetes and CVDs is also expected to fuel industry demand.

Cancer patients need continuous monitoring for evaluating their progress with regard to the prescribed treatment plan. Continuous monitoring enables doctors to evaluate and vary the dosage to eradicate tumor cells. Government initiatives such as various campaigns, health insurance policies, and reimbursement policies for medical devices present growth opportunities for the market, thereby augmenting the product demand. Moreover, advancements in technology, introduction of affordable and efficient devices, and improving healthcare infrastructure due to rapid economic growth would also propel market expansion.

The Germany remote patient monitoring device market is highly competitive and led by Medtronic Plc and St. Jude Medical, Inc. Other key companies are Boston Scientific Corporation, Covidien Ltd., and Philips Healthcare. Mergers and acquisitions are the key strategies undertaken by most of these companies to diversify their product portfolio and gain market share in the coming years.

Hexa Research has segmented the Germany remote patient monitoring devices market report based on product type, application and end use:

Segmentation by Product Type

    • Vital Sign Monitors

    • Specialized Monitors

Segmentation by Application

    • Cancer

    • Cardiovascular Diseases

    • Diabetes

    • Sleep Disorder

    • Weight Management

    • Fitness Monitoring

Segmentation by End Use

    • Hospital-based Patients

    • Ambulatory Patients

    • Home Healthcare

Key players analyzed:

    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

    • Nihon Kohden Corporation

    • Omron Corporation

    • OSI Systems, Inc.

    • Koninklijke Philips N.V.

    • Welch Allyn, Inc.

    • ALTEN Calsoft Labs

    • Smiths Medical, Inc.

    • Abbott Laboratories

    • American TeleCare, Inc.

    • Boston Scientific Corporation

    • Dräger Medical

    • GE Healthcare

    • Honeywell Life Care Solutions

    • Johnson & Johnson Services, Inc.

    • LifeWatch AG

    • Masimo

    • Medtronic PLC

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

China Scar Treatment Market is Projected to Reach USD 2.77 Billion by 2025

20 September 2018, The China Scar Treatment Market size is expected to reach USD 2.77 billion by 2025 owing to the increasing emphasis on appearance. In the current scenario, all demographic segments of the population lay great importance on enhancing their esthetic appeal. In addition, unsightly scars often cause a huge impact on a person’s quality of life. Scar treatment helps in achieving complete skin rejuvenation, which improves the esthetic appeal of a person.

Rising number of road accidents is considered to be one of the high-impact rendering factors for boosting the demand for scar treatment products. Moreover, increased number of cases of hypertrophic burn scars, wherein the victim’s appearance is distorted, has also resulted in high demand for scar treatment products in China.

China scar treatment market is witnessing considerable technological developments with the introduction of laser therapies. Moreover, plastic and reconstructive surgeries are one of the trending procedures adopted commonly to enhance esthetic appeal. These surgeries help remove various types of scars, which, in turn, rejuvenates the skin.

Browse Details of Report @ https://www.hexaresearch.com/research-report/china-scar-treatment-market

Topical products accounted for the largest market revenue share as they are available as Over-The-Counter (OTC) products, which enables self-care and provides an easy and inexpensive way of scar treatment. With increasing awareness among populations about scar treatment options, the use of topical products has been on the rise.

The laser products are anticipated to witness the highest growth over the projected period as they are an effective and painless approach of scar treatment. Furthermore, technological advancements have significantly fueled the demand for laser treatments to effectively reduce and remove scars. Hence, laser scar removal has evolved as an innovative approach in the field of scar treatment.

In terms of scar type, atrophic scars observed the highest growth owing to the increasing cases of acne scars. A majority of the population deals with acne as a common problem. Moreover, these scars are easily treated with OTC products like creams and gels and the treatment is easy and effective. Thus, increasing the demand for topical products would drive the scar treatment market.

Moreover, hypertrophic and keloid scars are expected to witness a significant growth over the projected period. These scars are a result of injuries and wounds caused mostly due to body piercings, burn injuries, road accidents, and cuts. Growing cases of contracture scars, caused by burn injuries of second and third degree, have resulted in an increased demand for skin treatment products over the past few years.

Hospitals accounted for the largest market share among the end-use segments owing to the availability of various treatment options for scars. Hospitals offer a generalized treatment for majority of the emergency care services and further provide care during the recovery period. Moreover, majority of the population in China prefers hospitals over clinics and OTC medicines for basic care, which is also expected to augment the segment growth.

Furthermore, retail pharmacies/e-commerce segment is expected to witness the highest growth due to the convenience offered by these retail stores.

Hexa Research has segmented the China scar treatment market report based on product, scar type and end use

Segmentation by Product

    • Topical Products

        • Creams

        • Gels

        • Silicon sheets

        • Others

    • Laser Products

        • CO2 Laser

        • Pulse-dyed Laser

        • Others

    • Injectables

    • Others

Segmentation by Scar Type

    • Atrophic scars

    • Hypertrophic & Keloid scars

    • Contracture scars

    • Stretch Marks

Segmentation by End Use

    • Hospitals

    • Clinics

    • Retail pharmacies/E-commerce

Key players analyzed:

    • Smith & Nephew PLC

    • LUMENIS

    • Sonoma Pharmaceuticals, Inc.

    • Molnlycke Health Care

    • Cynosure, Inc.

    • NewMedical Technology, Inc.

    • Suneva Medical, Inc.

    • Pacific World Corporation

    • Perrigo Company PLC

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

Hospital Information Systems (HIS) Market Research Report - Industry Analysis and Forecast to 2025

Global Hospital Information Systems (HIS) Market is expected to foresee a considerable growth over the forecast period. One of the crucial factors contributing to the HIS market growth is augmented demand for unconventional health monitoring systems. The global industry has been witnessing increased adoption of mobile devices and this trend is expected to continue over the forecast period. However, shortage of skillful professionals may pose a challenge to market growth in the coming years. Growing penetration of smartphones and mobile devices across the developed, as well as emerging economies, is anticipated to have a positive impact on the market growth.

These devices eliminate the need for patients to visit clinics or hospitals every time they require a diagnosis. They also provide regular updates regarding their illnesses enabling follow-ups and check-ups. Hence, mobile technologies are anticipated to advance healthcare facilities to a great extent over the forecast period. Rising need for advanced healthcare services on account of aging population and growing demand from patients is expected to boost the market over the forecast period. Furthermore, hi-tech technological developments, such as business intelligence and analytics, which help reduce the overall costs and provide improved results would also drive the market growth.

Browse Details of Report @ https://www.hexaresearch.com/research-report/hospital-information-systems-his-market

Rapid implementation of these systems in developing economies by the leading healthcare IT companies will also accelerate the market growth. Popular concept of emerging interrelated health systems, particularly in the healthcare and IT market, has led vendors to integrate necessary competencies to tap the growing market potential. Intense market merging activity has resurfaced over the last few years. This trend is anticipated to continue during the forecast period. Rapid technological developments coupled with growing government initiatives in improving health care facilities, particularly in emerging economies including India and China, is expected to fuel adoption of hospital information systems.

Efforts taken by various public and private firms for the development of global healthcare sector and substantial technological advances are also driving the adoption of HIS. Rapid demographic changes along with rising health concerns and health care costs have forced governments to boost the quality and outreach while simultaneously reducing related expenses. Governments around the world have been facing concerns to address financial limitations, as well as affordability and efficiency restraints of healthcare, due to rapidly growing population. IT has also forced governments to magnify their efforts in encouraging the adoption of HIS to upsurge clinical outcomes, as well as hospital productivity.

Substantial legislative and economic incentives have been offered by governments in North America, Europe, India, and China, to authorize digitalization of healthcare workflow. Growing demand and government funding for lesser errors and increased productivity have encouraged technological advancements in the healthcare IT industry. Amongst prominent technologies, which have considerably contributed to progressive adoption trends in this market are cloud-based and web-based HIS solutions. Software as a Service (SaaS) models have eliminated huge upfront costs associated with the acceptance of IT infrastructure, thereby escalating penetration of HIS into medium- and small-scale practices and among independent physicians.

Other technological improvements such as advanced clinical decision support systems and integrated speech recognition capabilities are also expected to continue contributing considerably in expanding the customer pool for HIS over the next few years. North America, Asia Pacific, Middle East and Africa (MEA), Europe, and Latin America are the major regional market for HIS. The North America region is anticipated to have the largest market share at the maximum growth rate followed by Asia Pacific and Europe.

Higher adoption of information systems in the region, particularly in U.S., due to growing implementation of IT services in the healthcare sector would dive the region’s growth. Numerous healthcare laws in the region, such as Affordable Care Act and Patient Protection Act, provide easy access to health insurance plans for consumers through subsidies. Most of these systems are being widely used in Arizona, Washington D.C., Colorado, Massachusetts, and New York.

Some of the key companies in the global Hospital Information Systems (HIS) market include McKesson Corp.; Siemens Healthcare Ltd.; Epic Systems Corp.; and Cerner Corp. Other companies are Healthcare Solutions Inc.; MEDHOST Solutions Corp. (Healthcare Management Systems Inc.); Computer Program and Systems, Inc.; NextGen Healthcare Information Systems LLC; Agfa Healthcare Corp.; CompuGroup Medical AG; Medical Information Technology, Inc. (MEDITECH); iSOFT Group PLC; Computer Sciences Corp.; Allscripts Healthcare Solutions, Inc.; Keane Care, Inc. (NTT Data Corp.); QuadraMed Corp.; and GE Healthcare.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-it-industry

Research Insights on Global Pharmerging Market Size, Share, Growth and Forecast to 2025

Global Pharmerging Market is anticipated to witness steady CAGR over the forecast period. Factors such as rising population due to low infant mortality rates and high focus on developing innovative drugs are expected to boost the growth. Among 17 emerging countries; China, India, and Russia are projected to hold a major market share in near future.

Patent expirations and availability of low cost generic drugs are anticipated to slow down sales in matured markets such as U.S, Europe, Japan, Canada, and U.K. As a result, major players are expected to bring in new products to maintain and even expand their industry share. This factor is likely to drive the pharmerging market in the forthcoming years. Launch of innovative products for diseases such as lupus, diabetes, arrhythmia, melanoma, prostate cancer, and osteoporosis among others may positively influence expansion in near future.

Macroeconomic factors such as greater awareness about drugs in semi-urban and rural markets and epidemiological changes are anticipated to propel growth of the market for pharmerging over the forecast period. High prevalence of age-related disorders and rapid development in private hospital industry are also expected to bode well for expansion. Increased healthcare expenditure by governments is expected to further drive growth.

Browse Details of Report @ https://www.hexaresearch.com/research-report/pharmerging-market

Emerging markets are likely to focus more on development of low cost generic drugs. This factor is anticipated to restrain growth of pharmerging in these regions. Changes in regulatory policies are likely to curb the growth as they have long-term impacts on pricing and medicine usage. Price sensitivity is another challenge likely to be faced by major companies. Regulatory norms such as the Affordable Care Act in U.S. and Japan’s price cut system are projected to rebalance spending priorities for markets.

Possibility of including major drugs under Drug Price Control Order (DPCO) may affect the retail and wholesale margins earned by chemists. Lower margins are further expected to lead to reduced production rates. Some of the major pharmaceutical companies which have experienced a negative growth rate due to DPCO include Sanofi-Aventis, Lupin, Zydus Cadila, etc. this factor is expected to negatively influence growth pharmerging.

On the basis of pharma growth requirements, pharmerging countries are categorized into tier-I, tier-II, and tier-III. Tier-I includes China while Tier-II includes India, Brazil, and Russia. Tier-III includes Turkey, Indonesia, Thailand, Vietnam, Egypt, South Africa and Mexico. China is a very complex market and is expected to focus on sophisticated operating models. Shrinking prices, complex distribution system, different commercial models in different provinces, and regulations favoring domestic manufacturers are the primary challenges faced by new entrants in China.

Indian market is expected to be highly fragmented and competitive. Strategic planning coupled with new product launches can help major pharmaceutical companies to be successful in this region. Adaption of local trends and strategic market entry can help new entrants. Russia is likely to be very volatile, due to price control system for essential drugs. Also, policies such as substitution of imported drugs with locally manufactured equivalents may pose a challenge to major players.

The market in Brazil is anticipated to be commoditized in retail segment as unmet medical needs are mostly satisfied by nonretail drugs. Establishment of CITEC/CONITEC is likely to act as a barrier for product inclusions in funding programs. Innovation is focused on niche private segments as demand for expenditure on complex therapies is usually avoided.

Major players operating in the market for pharmerging are AstraZeneca, Sanofi, Merck, Pfizer, GlaxoSmithKline, Novartis, Abbott Laboratories, CSL Behring, Johnson & Johnson, Sun Pharmaceutical, Aspen, Teva Pharmaceutical, Bayer, Valeant Pharmaceutical, Biogen, Baxter, STADA, Mylan, Takeda Pharma, Alexion Pharmaceuticals, and Endo Health Pharmaceuticals. The market is highly fragmented due to the presence of small and medium businesses. Product launches, mergers and acquisitions, and innovations are anticipated to define competition among top players. Majority of companies focus on merger and acquisitions to expand market presence and increase profits.

Major pharmaceutical companies are expected to deal with some uncertainties in terms of regulation and pricing policies laid down to ensure a profitability. Anticipation and analysis of compliance risks and implementation of suitable market entry strategies are some of the popular business strategies.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry